Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Antibody Discovery Services
Overview
Target Analysis & Immunization
Antibody Discovery & Characterization
Developability Profiling
Optimization & Engineering
Preclinical Services
Protein Production
Overview
 
Online Store

Explore now

See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
AI Technology
LENSai Applications
The LENSai Difference
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Resources
Antibody Discovery Resources
AI Technology Resources
IPA Collective
Resource Spotlight
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

HUB of
Biotherapeutic
Intelligence™
Company
Overview
Leadership
Investor Relations
Careers
Locations
Contact Us
News
News & Press Releases
Events
See our latest upcoming event
Tell me moreto Events
 
Connect with IPA

Contact usto Contact
Follow us on LinkedInto LinkedIn

In the News

Contact Us

IPA News
May 12th, 2025
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ:IPA) a leader in AI-driven biotherapeutics, is pleased to announce today new benchmarking results that validate the accuracy and utility of its in silico epitope mapping...
April 11th, 2025
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods
AUSTIN, Texas - ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA) a leader in AI-driven biotherapeutics, today announced its strong support for the U.S. Food and Drug Administration’s (FDA) recent decision to phase out animal testing requirements...
March 13th, 2025
ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics
Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell Platforms Partnership advances next-generation ADCs and bispecific antibodies to address unmet medical needs AUSTIN, Texas - ImmunoPrecise Antibodies Ltd....
February 26th, 2025
IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody discovery and development, today announced a strategic collaboration with RIBOPRO, a pioneering...
February 24th, 2025
ImmunoPrecise Antibodies Announces Key Leadership Changes
AUSTIN, Texas--(BUSINESS WIRE)-- ImmunoPrecise Antibodies (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, is pleased to announce key leadership updates, including the appointment of Kamil Isaev...
September 26th, 2024
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
Rabbit B Cell Select ® Drives Clinical Breakthroughs in Cancer Treatment VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”)...
November 13th, 2023
BioStrand® Unveils a Revolutionary Approach to Biological Sequence Retrieval: A Fusion of Natural Language Processing and Database Research
VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”), a leader in AI-driven biotherapeutic research and technology, is thrilled to announce that its subsidiary,...
June 29th, 2023
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2023 on July 7th, 2023.
The Company to host an earnings conference call via webcast VICTORIA, British Columbia, June 29, 2023 - IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven biotherapeutic research and technology, today...
April 24th, 2023
LENSᵃⁱ Update: IPA’s BioStrand LENSᵃⁱ™ integrates advanced HYFT™ technology to enhance LLMs and accelerate antibody discovery.
Dr. Dirk Van Hyfte, Head of Innovation and Co-Founder at BioStrand, stated, “The integration of HYFT technology into our LLMs marks a transformative moment in biotechnology." See full announcement
March 23rd, 2023
ImmunoPrecise Presents Novel T-Cell Engaging Bispecific Antibodies Addressing a Unique Oncological Target, Tropomyosin Receptor Kinase B, Associated with Poor Prognosis and Survival Rates
Company to Present at the Upcoming 2023 Annual Meeting of the American Association for Cancer Research (AACR) ImmunoPrecise’s Unique Proprietary Bispecific Antibodies Link Cells Expressing Tumor-Associated Antigen Tropomyosin Receptor Kinase B...
March 16th, 2023
IPA Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2023
IPA’s Project revenue increased by 16.7% compared to the prior year, driven by the growth of the company's proprietary B cell Select® platform and protein manufacturing services. Talem Therapeutics has announced a collaboration with Libera Bio to...
March 15th, 2023
ImmunoPrecise Antibodies’ Subsidiary Talem Therapeutics Announces a Multi-Target AI-Driven Antibody Discovery Collaboration with Libera Bio
The program will leverage BioStrand’s LENSai® Full Suite of Integrated Intelligence Technology® with Libera Bio’s Multifunctional Polymeric Nanocapsules (MPN Technology®) The Alliance has Stipulated a Minimum of Upfront and Downstream Milestone...